What it is
GLR-3 refers to Retatrutide (LY3437943), an investigational peptide being studied in metabolic disease and obesity research.
Mechanism and research questions
- It is designed to activate GIP, GLP-1, and glucagon receptors.
- Structural studies have examined retatrutide-bound receptor complexes, including GCGR and GLP-1R.
Human evidence
The Phase 2 trial included adults with obesity or overweight plus a weight-related condition. Gastrointestinal adverse events were common and dose-related in the PubMed abstract.
Preclinical / mechanistic evidence
Receptor and structural research supports the intended multi-receptor pharmacology, but does not establish an approved use for research-vial material.
Evidence summary
A randomized Phase 2 obesity trial reported dose-dependent weight changes over 48 weeks; Phase 3 research remains a separate evidence stage.
Limits and interpretation
- Retatrutide remains investigational in the reviewed sources.
- Trial findings cannot be converted into individual treatment advice or guaranteed outcomes.
- Research material is not equivalent to an approved pharmaceutical product.
Regulatory and identity note
Investigational; do not describe catalog material as FDA-approved or as a prescription product.
GLR-3 is a display label only; it does not change the identity, regulatory status, or legal characterization of Retatrutide / LY3437943. Keep the canonical identity visible and do not treat GLR-3 as a substitute for identity verification.